AVA6103 is a FAP-enabled pre|CISION&#174;peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activity

AVA-6103 - Avacta

https://www.abstractsonline.com/pp8/#!/21436/presentation/5743

Curtis Rink1; Tom Clough1; Ellen Watts1; Folake Orafidiya1; Marine Houée1; Sophie Brown1; Victoria Juskaite1; Gezim Lahu2; Ruairidh Edwards3; Karen Campbell3; Dave Liebowitz3; David Jones1; Francis Wilson1; Michelle Morrow1

Mar 18, 2026